Marian W. Wentworth is President and Chief Executive Officer of MSH. A leader in managing complex international public health initiatives across diverse cultures, she uses her private sector and nonprofit acumen to address global health challenges from new vantage points. Since 2017, Wentworth has helped MSH make highly effective, sustainable systemic improvements in some of the globe’s most challenging environments. 

Before coming to MSH, Wentworth managed global strategy for marketing, manufacturing, and research at Merck & Co for more than 25 years, including the company’s $6 billion dollar vaccines business. A champion for adolescent health, she led the global sales and marketing launch of the world’s first cervical cancer vaccine, Gardasil. She also managed adult vaccines for shingles, influenza, pneumococcal disease, hepatitis B, hepatitis A, and tetanus. Earlier in her career, Wentworth was a consultant in operations management at Arthur D. Little, Inc.

Sharing her substantial experience in the vaccine market, Wentworth serves on the Value of Vaccination Research Network (VoVRN) Steering Committee and WHO’s Product Development for Vaccines Advisory Committee (PDVAC). As of January 2020, she is a visiting scholar at Drexel University’s Dornsife School of Public Health.

Wentworth has a B.A. in mathematics from Harvard University.